How persons with chronic hepatitis C in residential substance abuse treatment programs think about depression and interferon therapy

Mary T. Rosedale, Shiela M. Strauss

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: This secondary analysis of existing qualitative descriptive data is the first to specifically report on how persons undergoing residential treatment for substance abuse think about depression and the risks of neuropsychiatric side effects associated with interferon (IFN) treatment for hepatitis C virus (HCV) infection. METHOD: Krippendorff's method for qualitative content analysis was used to describe patient perspectives about psychiatric symptoms and potential side effects of IFN treatment. Transcripts from face-to-face, semistructured interviews with 20 patients in 3 residential substance abuse treatment programs were analyzed. RESULTS: Themes included patients' powerlessness and their evaluation of risk and confidence. Participants commented that residential substance abuse treatment programs offered a unique opportunity to undergo antiviral treatment because they capitalized on a patient's heightened readiness for change. Barriers to treatment included perceived obstacles, such as compulsory waiting periods before treatment initiation, fear that neuropsychiatric treatment side effects would sabotage addiction recovery, and concern that psychiatric providers lacked sufficient HCV knowledge. However, when patients perceived clinicians as knowledgeable and genuinely caring, they were amenable to considering antiviral treatment. CONCLUSION: Increasing HCV-specific psychiatric education and staff training, exploring combined psychiatric and antiviral treatment combinations, and therapeutically supporting patient decision making are needed to better use substance abuse residential treatment programs as sites for treating HCV infection. Novel antidepressant treatment approaches are required in this population. Advanced practice psychiatric nurses are well-positioned to develop new integrative models of care addressing the medical, psychiatric, and substance abuse comorbidities in this highly vulnerable group.

Original languageEnglish (US)
Pages (from-to)350-356
Number of pages7
JournalJournal of the American Psychiatric Nurses Association
Volume16
Issue number6
DOIs
StatePublished - Nov 2010

Fingerprint

Chronic Hepatitis C
Interferons
Substance-Related Disorders
Depression
Psychiatry
Hepacivirus
Therapeutics
Residential Treatment
Antiviral Agents
Virus Diseases
Antidepressive Agents
Fear
Comorbidity
Decision Making
Nurses
Interviews
Education

Keywords

  • alcohol and drug abuse
  • community residences
  • depression
  • dual diagnoses
  • mental illness and alcohol/drug abuse
  • models/theories of psychiatric nursing

ASJC Scopus subject areas

  • Phychiatric Mental Health

Cite this

How persons with chronic hepatitis C in residential substance abuse treatment programs think about depression and interferon therapy. / Rosedale, Mary T.; Strauss, Shiela M.

In: Journal of the American Psychiatric Nurses Association, Vol. 16, No. 6, 11.2010, p. 350-356.

Research output: Contribution to journalArticle

@article{1604af32d8f14ce2aab73c757e9cb354,
title = "How persons with chronic hepatitis C in residential substance abuse treatment programs think about depression and interferon therapy",
abstract = "OBJECTIVE: This secondary analysis of existing qualitative descriptive data is the first to specifically report on how persons undergoing residential treatment for substance abuse think about depression and the risks of neuropsychiatric side effects associated with interferon (IFN) treatment for hepatitis C virus (HCV) infection. METHOD: Krippendorff's method for qualitative content analysis was used to describe patient perspectives about psychiatric symptoms and potential side effects of IFN treatment. Transcripts from face-to-face, semistructured interviews with 20 patients in 3 residential substance abuse treatment programs were analyzed. RESULTS: Themes included patients' powerlessness and their evaluation of risk and confidence. Participants commented that residential substance abuse treatment programs offered a unique opportunity to undergo antiviral treatment because they capitalized on a patient's heightened readiness for change. Barriers to treatment included perceived obstacles, such as compulsory waiting periods before treatment initiation, fear that neuropsychiatric treatment side effects would sabotage addiction recovery, and concern that psychiatric providers lacked sufficient HCV knowledge. However, when patients perceived clinicians as knowledgeable and genuinely caring, they were amenable to considering antiviral treatment. CONCLUSION: Increasing HCV-specific psychiatric education and staff training, exploring combined psychiatric and antiviral treatment combinations, and therapeutically supporting patient decision making are needed to better use substance abuse residential treatment programs as sites for treating HCV infection. Novel antidepressant treatment approaches are required in this population. Advanced practice psychiatric nurses are well-positioned to develop new integrative models of care addressing the medical, psychiatric, and substance abuse comorbidities in this highly vulnerable group.",
keywords = "alcohol and drug abuse, community residences, depression, dual diagnoses, mental illness and alcohol/drug abuse, models/theories of psychiatric nursing",
author = "Rosedale, {Mary T.} and Strauss, {Shiela M.}",
year = "2010",
month = "11",
doi = "10.1177/1078390310392784",
language = "English (US)",
volume = "16",
pages = "350--356",
journal = "Journal of the American Psychiatric Nurses Association",
issn = "1078-3903",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - How persons with chronic hepatitis C in residential substance abuse treatment programs think about depression and interferon therapy

AU - Rosedale, Mary T.

AU - Strauss, Shiela M.

PY - 2010/11

Y1 - 2010/11

N2 - OBJECTIVE: This secondary analysis of existing qualitative descriptive data is the first to specifically report on how persons undergoing residential treatment for substance abuse think about depression and the risks of neuropsychiatric side effects associated with interferon (IFN) treatment for hepatitis C virus (HCV) infection. METHOD: Krippendorff's method for qualitative content analysis was used to describe patient perspectives about psychiatric symptoms and potential side effects of IFN treatment. Transcripts from face-to-face, semistructured interviews with 20 patients in 3 residential substance abuse treatment programs were analyzed. RESULTS: Themes included patients' powerlessness and their evaluation of risk and confidence. Participants commented that residential substance abuse treatment programs offered a unique opportunity to undergo antiviral treatment because they capitalized on a patient's heightened readiness for change. Barriers to treatment included perceived obstacles, such as compulsory waiting periods before treatment initiation, fear that neuropsychiatric treatment side effects would sabotage addiction recovery, and concern that psychiatric providers lacked sufficient HCV knowledge. However, when patients perceived clinicians as knowledgeable and genuinely caring, they were amenable to considering antiviral treatment. CONCLUSION: Increasing HCV-specific psychiatric education and staff training, exploring combined psychiatric and antiviral treatment combinations, and therapeutically supporting patient decision making are needed to better use substance abuse residential treatment programs as sites for treating HCV infection. Novel antidepressant treatment approaches are required in this population. Advanced practice psychiatric nurses are well-positioned to develop new integrative models of care addressing the medical, psychiatric, and substance abuse comorbidities in this highly vulnerable group.

AB - OBJECTIVE: This secondary analysis of existing qualitative descriptive data is the first to specifically report on how persons undergoing residential treatment for substance abuse think about depression and the risks of neuropsychiatric side effects associated with interferon (IFN) treatment for hepatitis C virus (HCV) infection. METHOD: Krippendorff's method for qualitative content analysis was used to describe patient perspectives about psychiatric symptoms and potential side effects of IFN treatment. Transcripts from face-to-face, semistructured interviews with 20 patients in 3 residential substance abuse treatment programs were analyzed. RESULTS: Themes included patients' powerlessness and their evaluation of risk and confidence. Participants commented that residential substance abuse treatment programs offered a unique opportunity to undergo antiviral treatment because they capitalized on a patient's heightened readiness for change. Barriers to treatment included perceived obstacles, such as compulsory waiting periods before treatment initiation, fear that neuropsychiatric treatment side effects would sabotage addiction recovery, and concern that psychiatric providers lacked sufficient HCV knowledge. However, when patients perceived clinicians as knowledgeable and genuinely caring, they were amenable to considering antiviral treatment. CONCLUSION: Increasing HCV-specific psychiatric education and staff training, exploring combined psychiatric and antiviral treatment combinations, and therapeutically supporting patient decision making are needed to better use substance abuse residential treatment programs as sites for treating HCV infection. Novel antidepressant treatment approaches are required in this population. Advanced practice psychiatric nurses are well-positioned to develop new integrative models of care addressing the medical, psychiatric, and substance abuse comorbidities in this highly vulnerable group.

KW - alcohol and drug abuse

KW - community residences

KW - depression

KW - dual diagnoses

KW - mental illness and alcohol/drug abuse

KW - models/theories of psychiatric nursing

UR - http://www.scopus.com/inward/record.url?scp=79551570343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551570343&partnerID=8YFLogxK

U2 - 10.1177/1078390310392784

DO - 10.1177/1078390310392784

M3 - Article

VL - 16

SP - 350

EP - 356

JO - Journal of the American Psychiatric Nurses Association

JF - Journal of the American Psychiatric Nurses Association

SN - 1078-3903

IS - 6

ER -